MediWound (NASDAQ:MDWD) Stock, Quote.Headers.trade-ideas

MediWound

MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.

Warsaw,,Poland,-,May,2020:,Accenture,Company,Logo,On,Office

News

Price Target

Markets

Trading Ideas

ITGR

MDWD

NCNO

NVTS

SNOW

URBN

VIGL

Accenture To Rally More Than 24%? Here Are 10 Top Analyst Forecasts For Thursday

Analysts

Initiation

Analyst Ratings

AVTX

CSGP

SMMT

This CoStar Group Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

urban_outfitters

Pre-Market Outlook

ADSK

HTHT

IREN

NTNX

Urban Outfitters To Rally Around 47%? Here Are 10 Top Analyst Forecasts For Wednesday

MediWound Ltd

Press Releases

General

MediWound to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

MediWound Initiates the VALUE Global Phase III Pivotal Trial of EscharEx® for Treatment of Venous Leg Ulcers

MediWound to Present at the 45th Annual TD Cowen Health Care Conference

MediWound Announces Phase III CIDS Publication on NexoBrid® for Pediatric Burn Care

MediWound to Report Fourth Quarter and Full Year 2024 Financial Results

Earnings

MediWound Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Health Care

MediWound to Present New EscharEx® Data at Leading Wound Care Conferences

MediWound to Report First Quarter 2025 Financial Results

Biotech

MediWound Announces Publication of Phase II EscharEx® Data Demonstrating Superiority Over Collagenase in Venous Leg Ulcers

MediWound Reports First Quarter 2025 Financial Results and Provides Corporate Update

Comments

MediWound

MediWound (NASDAQ:MDWD) Stock, Quote.Headers.trade-ideas

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell